Can topical ketoconazole cause gynaecomastia? This is a reasonable concern, given that oral ketoconazole carries well-documented hormonal side effects, including breast tissue enlargement in males. However, topical formulations — such as ketoconazole 2% shampoo and cream — work very differently from their oral counterparts. Because percutaneous absorption is negligible under normal conditions of use, the drug is unlikely to reach systemic concentrations sufficient to disrupt steroid hormone pathways. This article explores the pharmacology behind ketoconazole-related gynaecomastia, what UK regulatory guidance says, and when to seek clinical advice.

How Ketoconazole Affects Hormone Levels in the Body

Oral ketoconazole inhibits CYP17A1 and CYP11A1 enzymes, reducing testosterone synthesis and raising the oestrogen-to-androgen ratio, which can cause true gynaecomastia — glandular breast tissue enlargement in males.

Have any more questions about this? Message our pharmaceutical team to get more info →

Ketoconazole is an imidazole antifungal agent that works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. However, its pharmacological activity extends beyond antifungal effects. At higher systemic concentrations — typically achieved with oral dosing — ketoconazole also inhibits several cytochrome P450 enzymes involved in human steroidogenesis, including CYP17A1 and CYP11A1. These enzymes are essential for the production of androgens such as testosterone, as well as cortisol. This mechanism is well documented in the EMA CHMP (2013) safety communication on oral ketoconazole and is reflected in the BNF monograph for the drug.

This dual inhibition can lead to a measurable reduction in circulating testosterone levels and, in some cases, a relative increase in the oestrogen-to-androgen ratio. It is this hormonal imbalance — specifically, elevated oestrogen activity relative to androgens — that underpins the development of gynaecomastia, the benign enlargement of glandular breast tissue in males. It is worth distinguishing true gynaecomastia (proliferation of glandular tissue, typically presenting as a firm, rubbery disc beneath the areola) from pseudogynaecomastia (fatty tissue deposition without glandular proliferation), as the two have different clinical implications and causes. True gynaecomastia can present as:

• Tenderness or swelling beneath one or both nipples

• A firm, rubbery disc of tissue beneath the areola

• Occasional mild discomfort

Understanding this mechanism is important when evaluating whether topical formulations of ketoconazole carry the same hormonal risks as their oral counterparts. The route of administration plays a critical role in determining how much of the drug reaches systemic circulation and, therefore, whether it can meaningfully interfere with steroid hormone pathways.

Topical Versus Oral Ketoconazole: Key Differences in Absorption

Topical ketoconazole produces negligible systemic absorption under normal conditions of use, meaning it is unlikely to reach concentrations sufficient to inhibit steroidogenic enzymes or affect hormone levels.

The distinction between topical and oral ketoconazole is clinically significant, particularly when assessing the risk of systemic side effects such as gynaecomastia. Oral ketoconazole tablets are absorbed through the gastrointestinal tract and achieve substantial plasma concentrations, enabling the drug to exert systemic effects on hepatic enzyme activity and steroid biosynthesis. It is for this reason that oral ketoconazole carries well-documented endocrine-related adverse effects.

Topical ketoconazole — available in the UK as shampoos (typically 2%) and creams — is designed for localised application to the skin or scalp. Percutaneous absorption is generally very low under normal conditions of use. According to the Summary of Product Characteristics (SmPC) for Nizoral 2% shampoo and ketoconazole 2% cream (as listed on the electronic Medicines Compendium, emc), systemic plasma levels following topical application are negligible or undetectable in most individuals when the product is used as directed. This pharmacokinetic profile means the drug is unlikely to reach concentrations sufficient to inhibit steroidogenic enzymes in a clinically meaningful way.

That said, absorption can be influenced by several factors:

• Skin integrity: Broken, inflamed, or compromised skin may allow greater absorption

• Surface area: Application over large body surface areas increases total drug exposure

• Occlusion: Covering treated areas with dressings or tight clothing can enhance penetration

• Frequency of use: More frequent or prolonged application may incrementally raise systemic levels

For these reasons, topical ketoconazole should not be applied to large surface areas, broken or inflamed skin, or under occlusion unless specifically directed by a clinician. For the vast majority of patients using topical ketoconazole as directed — for example, applying a 2% shampoo to the scalp for dandruff or seborrhoeic dermatitis — systemic absorption remains well below the threshold required to affect hormone levels.

Is Gynaecomastia a Recognised Side Effect of Topical Ketoconazole?

Gynaecomastia is not listed as an adverse effect in the UK SmPCs for topical ketoconazole products; it is a recognised risk only with oral formulations due to systemic enzyme inhibition.

Gynaecomastia is a recognised adverse effect of oral ketoconazole, and this association is well established in the medical literature and reflected in the drug's prescribing information. The mechanism, as outlined above, relates to systemic inhibition of testosterone synthesis. However, the picture is considerably different for topical formulations.

Currently, there is no recognised link between topical ketoconazole and gynaecomastia in UK regulatory or clinical documentation. The SmPCs for topical ketoconazole products licensed in the UK — including Nizoral 2% shampoo and ketoconazole 2% cream (emc) — do not list gynaecomastia as a known adverse effect. This is consistent with the expectation that systemic absorption from topical use is insufficient to produce clinically relevant hormonal disruption.

In clinical practice, if a patient using topical ketoconazole develops gynaecomastia, it is far more likely that the cause lies elsewhere. According to NICE CKS guidance on gynaecomastia, common causes to consider include:

• Other medications (e.g., spironolactone, finasteride, antipsychotics, some antihypertensives)

• Underlying hormonal conditions (e.g., hypogonadism, hyperthyroidism, liver disease)

• Physiological causes (e.g., puberty, ageing)

• Recreational drug or alcohol use

A thorough medication review and clinical assessment are essential before attributing gynaecomastia to topical ketoconazole. Patients are encouraged to report any suspected adverse drug reactions — including unexpected hormonal changes — via the MHRA Yellow Card scheme (https://yellowcard.mhra.gov.uk/).

What the Clinical Evidence and MHRA Guidance Says

The MHRA and EMA restricted oral ketoconazole due to hepatotoxicity and endocrine risks, but explicitly did not extend these hormonal warnings to topical ketoconazole formulations.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued an important Drug Safety Update in 2013 regarding oral ketoconazole, restricting and ultimately suspending its use for superficial fungal infections in the UK. This decision was driven primarily by the risk of serious hepatotoxicity, with endocrine side effects — including gynaecomastia and adrenal insufficiency — also cited as concerns at systemic doses. The European Medicines Agency (EMA) CHMP reached the same conclusion, recommending suspension of oral ketoconazole marketing authorisations across the EU for non-life-threatening indications.

Critically, neither the MHRA nor the EMA extended these endocrine-related warnings to topical ketoconazole formulations. Products such as Nizoral 2% shampoo remain available over the counter in the UK and are considered safe for use as directed, without the hormonal risk profile associated with systemic administration. The emc SmPC for Nizoral 2% shampoo confirms this distinction explicitly.

From an evidence-based perspective, no large-scale randomised controlled trials or systematic reviews have identified gynaecomastia as an outcome associated with topical ketoconazole use. Clinicians and patients can therefore be reassured that, based on current evidence and regulatory guidance, topical ketoconazole used appropriately does not carry a meaningful risk of causing gynaecomastia. Any concerns about new or unexplained breast tissue changes should nonetheless prompt a clinical review. Suspected adverse reactions to any medicine, including topical ketoconazole, can be reported to the MHRA via the Yellow Card scheme.

When to Speak to a GP or Pharmacist About Skin Treatment Side Effects

Patients should contact a GP promptly for any new breast swelling or lump during topical ketoconazole use; hard or irregular lumps require urgent 2-week-wait referral to exclude breast cancer per NICE NG12.

Whilst topical ketoconazole is generally well tolerated, it is important for patients to remain vigilant about any unexpected changes during treatment. Most side effects associated with topical use are localised and mild, including skin irritation, dryness, or contact dermatitis at the application site. These typically resolve on stopping the product or switching to an alternative.

Patients should contact their GP or pharmacist promptly if they notice any of the following during or after using topical ketoconazole:

• Breast swelling, tenderness, or a lump beneath the nipple area — whilst very unlikely to be caused by topical ketoconazole, any new breast change in males warrants prompt assessment

• Persistent or worsening skin reactions, including redness, blistering, or signs of allergic contact dermatitis

• No improvement in the fungal condition after the recommended treatment duration, which may suggest an alternative diagnosis or resistant organism

Pharmacists are well placed to advise on correct application technique, appropriate duration of use, and whether a prescription-strength product or alternative treatment may be more suitable.

If gynaecomastia is identified during a consultation, the GP will typically take a full history, examine the breast tissue (to distinguish true gynaecomastia from pseudogynaecomastia), and review the full medication list. Initial investigations in line with NICE CKS guidance on gynaecomastia may include: morning testosterone and sex hormone-binding globulin (SHBG), LH, FSH, oestradiol, prolactin, hCG, thyroid function tests (TFTs), and liver function tests (LFTs). Testicular examination is also recommended to exclude a testicular cause.

Important — red flags requiring urgent referral: In accordance with NICE NG12 (Suspected Cancer: Recognition and Referral), men presenting with a hard or irregular breast lump, unilateral nipple changes (such as discharge, retraction, or ulceration), skin changes overlying the breast, or palpable axillary lymph nodes should be referred urgently via the 2-week-wait pathway to exclude breast cancer. Men aged 50 or over with unilateral nipple changes should also be referred urgently. These features are distinct from the soft, symmetrical, tender tissue typical of benign gynaecomastia and must not be overlooked.

Safer Alternatives and Managing Your Treatment Plan

Alternatives to ketoconazole shampoo include selenium sulphide, ciclopirox olamine, and coal tar; for cutaneous infections, topical terbinafine or clotrimazole are commonly used first-line options per BNF guidance.

For patients who are concerned about the potential — however unlikely — hormonal effects of ketoconazole, or who have experienced adverse reactions, several alternative antifungal treatments are available in the UK. The choice of alternative depends on the underlying condition being treated.

For seborrhoeic dermatitis and dandruff, alternatives to ketoconazole shampoo include:

• Selenium sulphide shampoo (e.g., Selsun) — effective for scalp conditions with a different mechanism of action and available in the UK

• Piroctone olamine shampoos — available in some over-the-counter formulations in the UK

• Coal tar preparations — useful for scalp psoriasis and seborrhoeic dermatitis, though less cosmetically acceptable to some patients

• Ciclopirox olamine shampoo (e.g., Stieprox 1.5%) — a licensed UK antifungal shampoo with a distinct mechanism

Note: Zinc pyrithione, previously a common ingredient in anti-dandruff shampoos, has had its regulatory status reviewed in the UK and EU; patients should check current product availability with a pharmacist.

For cutaneous fungal infections such as tinea corporis or tinea pedis, topical terbinafine (an allylamine antifungal) or clotrimazole (another imidazole) are commonly used first-line alternatives with well-established safety profiles, as reflected in the BNF and NHS guidance on managing fungal skin infections.

When managing any long-term skin condition requiring antifungal treatment, it is good practice to:

• Use the lowest effective concentration for the shortest necessary duration

• Avoid applying to large surface areas, broken skin, or under occlusion unless specifically directed by a clinician

• Review treatment regularly with a GP or dermatologist to ensure it remains appropriate

• Report any new or unexpected symptoms promptly, particularly if they appear unrelated to the skin condition being treated

• Report suspected adverse reactions to the MHRA via the Yellow Card scheme (https://yellowcard.mhra.gov.uk/)

Overall, topical ketoconazole remains a safe and effective option for many patients when used as directed. Concerns about gynaecomastia should not deter appropriate use, but open communication with a healthcare professional ensures that any unexpected changes are assessed promptly and managed appropriately.

Frequently Asked Questions